Article
A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.
Scientific reports - 1 Jul 2021
Palit Sander A L, van Dorp Jeroen, Vis Daniel, Lieftink Cor, Linder Simon, Beijersbergen Roderick, Bergman Andries M, Zwart Wilbert, van der Heijden Michiel S
Abstract excerpt
Resistance to drugs targeting the androgen receptor (AR) signaling axis remains an important challenge in the treatment of prostate cancer patients. Activation of alternative growth pathways is one mechanism used by cancer cells to proliferate despite treatment, conferring drug resistance. Through a kinome-centered CRISPR-Cas9 screen in CWR-R1 prostate cancer cells, we identified activated BRAF signaling as a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.